Vaccines: Past, present and future

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S5-

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; STAPHYLOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; TYPHOID VACCINE; VACCINE;

ACTIVE IMMUNIZATION; ADOLESCENCE; CELL CULTURE; CHINA; CIVIL DEFENSE; CYTOMEGALOVIRUS; DENGUE VIRUS; DRUG COST; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC ENGINEERING; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HERPES SIMPLEX; HISTORY OF MEDICINE; HOSPITAL PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANCY; INFECTION; MALARIA; MYCOBACTERIUM BOVIS; NON PROFIT ORGANIZATION; PARAINFLUENZA VIRUS; PASTEURELLA MULTOCIDA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SMALLPOX; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS INACTIVATION; WAR; WART VIRUS; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ALLERGY AND IMMUNOLOGY; BACTERIAL INFECTIONS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS; VACCINATION; VACCINES; VIRUS DISEASES;

ANTHRAX; CYTOMEGALOVIRUS; DENGUE VIRUS; FLAVIVIRUS; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE B; HERPES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; PASTEURELLA MULTOCIDA; PNEUMOCOCCUS; SARS CORONAVIRUS; STAPHYLOCOCCUS; STREPTOCOCCUS; VARIOLA VIRUS; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 17644390191     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1209     Document Type: Article

References (87)

1. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. & Ladnyi, I.D. Early efforts at control: Variolation, vaccination, and isolation and quarantine. in History of International Public Health, No. 6 (eds Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D.) 245-276 (World Health Organization, Geneva, 1988).
2. Plotkin, S.L. & Plotkin, S.A. A short history of vaccination. in Vaccines 4th edn (eds. Plotkin, S.A. & Orenstein, W.A.) 1-15 (W.B. Saunders, Philadelphia, 2004).
3. Fenn, E.A. Pox Americana: The Great Smallpox Epidemic of 1775-82. 1 (Hill and Wang, New York, 2001).
4. Pasteur, L. De l’attenuation du virus du cholera des poules. C. R. Acad. Sci. Paris 91, 673-680 (1880).
5. Pasteur, L., Chamberland, C.-E.: Sur la vaccination charbonneuse. C. R. Acad. Sci. Paris 92, 1378-1383 (1881).
6. Calmette, A., Guerin, C., Breton, M. Contribution a l’etude de la tuberculose experimental du cobaye (infection et essais de vaccination par la voie digestive). Ann. Inst. Pasteur Paris 21, 401-416 (1907).
7. Theiler, M., Smith, H.H. The use of yellow fever virus by in vitro cultivation for human immunization. J. Exp. Med. 65, 787-800 (1937).
8. Weller, T.H. Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proc. Soc. Exp. Biol. Med. 72, 153-155 (1949).
9. Kilbourne, E.D. & Murphy, J.S. Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. J. Exp. Med. 111, 387-406 (1960).
10. Clark, H.F., Offit, P., Glass, R.I., Ward, R.L. Rotavirus vaccines. in Vaccines 4th edn. (eds. Plotkin, S.A. & Orenstein, W.A.) 1327-1345 (Elsevier, Philadelphia, 2004).
11. Bernstein, D.I. et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 16, 381-387 (1998).
12. Salmon, D.E. & Smith, T. On a new method of producing immunity from infectious diseases. Am. Vet. Rev. 10, 63-69 (1886).
13. Ramon, G. Sur le pouvoir floculant et sur les proprietes immunisantes d’une toxine diphterique rendu anatoxique (anatosine). C. R. Acad. Sci. Paris 177, 1338-1340 (1923).
14. Ramon, G. & Zeller, C. De la valeur antigenique de l’anatoxine tetanique chez l’homme. C. R. Acad. Sci. Paris 182, 245-247 (1926).
15. Schneerson, R., Barrera, O., Sutton, A. & Robbins, J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152, 361-376 (1980).
16. Moingeon, P. Cancer vaccines. Vaccine 9, 1305-1326 (2001).
17. McAleer, W.J., Buynak, E.B., Maigetter, R.Z., Wampler, D.E., Miller, W.J. & Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307, 178-180 (1984).
18. Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J. & Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report. Hepatology 1, 377-385 (1981).
19. Fikrig, E., Barthold, S.W., Kantor, F.S. & Flavell, R.A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250, 553-556 (1990).
20. Spaete, R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant. Proc. 23, 90-96 (1991).
21. Pizza, M. et al. Mutants of pertussis toxin suitable for vaccine development. Science 246, 497-500 (1989).
22. Durbin, A.P. & Karron, R.A. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin. Infect. Dis. 37, 1668-1677 (2003).
23. Guirakhoo, F. et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetrava- lent vaccine formulations in nonhuman primates. J. Virol. 78, 4761-4775 (2004).
24. Plotkin, S.A. Six revolutions in vaccinology. Pediatr. Infect. Dis. J. 24, 1-9 (2005)
25. Excler, J.L. & Plotkin, S. The prime-boost concept applied to HIV preventive vaccines. AIDS 11 Suppl A, S127-S137 (1997).
26. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20, 1949-1955 (2002).
27. Moore, A.C. & Hill, A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143 (2004).
28. Rayner, J.O., Dryga, S.A. & Kamrud, K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 12, 279-296 (2002).
29. Schiller, J.T. & Davies, P. Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol. 2, 343-347 (2004).
30. Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
31. Huang, Y., Yang, Z.-Y., Kong, W.P. & Nabel, G.J. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: Implications for assembly and vaccine production. J. Virol. 78, 12557-12565 (2004).
32. Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993).
33. Robinson, H.L. Nucleic acid vaccines: An overview. Vaccine 15, 785-787 (1997).
34. Reddy, S.T. & Ertl, H.C. The potential use of DNA vaccines for neonatal immunization. Cur.r. Opin. Mol. Ther. 1, 22-29 (1999).
35. Neumann, G. et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96, 9345-9350 (1999).
36. Palese, P. & Garcia, S.A. Influenza vaccines: Present and future. J. Clin. Invest. 110, 9-13 (2002).
37. Wood, J.M. & Robertson, J.S. From lethal virus to life-saving vaccine: Developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842-847 (2004).
38. Mora, M., Veggi, D., Santini, L., Pizza, M. & Rappuoli, R. Reverse vaccinology. Drug Discov. Today 8, 459-464 (2003).
39. Dhiman, N., Bonilla, R., O’Kane, D.J. & Poland, G.A. Gene expression microarrays: A 21st century tool for directed vaccine design. Vaccine 20, 22-30 (2001).
40. Serruto, D., Adu-Bobie, J., Capecchi, B., Rappuoli, R., Pizza, M. & Masignani, V. Biotechnology and vaccines: Application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J. Biotechnol. 113, 15-32 (2004).
41. Lambert, P-H. Companion paper. Nat. Med. 11 Suppl 1, S54-S62 (2005).
42. Plotkin, S.A. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63-75 (2001).
43. BenMohamed, L., Wechsler, S.L. & Nesburn, A.B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis. 2, 425-431 (2002).
44. Moingeon, P., Haensler, J. & Lindberg, A. Towards the rational design of Th1 adjuvants. Vaccine 19, 4363-4372 (2001).
45. Autran, B., Molet, L. & Lederman, M.M. Host defenses against viral infection. in Practical Guidelines in Antiviral Therapy (eds. Boucher, C.A. & Galasso, G.A) 65-94 (Elsevier, Philadelphia, 2002).
46. O’Garra, A. & Vieira, P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10, 801-805 (2004).
47. Decker, M.D., Edwards, K.M. & Bogaerts, H.H. Combination vaccines. in Vaccine 4th edn. (eds. Plotkin, S.A. & Orenstein, W.A.) 825-861 (Elsevier, Philadelphia, 2004)
48. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-258 (2004).
49. Sela, M. & Hilleman, M.R. Therapeutic vaccines: Realities of today and hopes for tomorrow. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14559 (2004).
50. Vandepapeliere, P. Therapeutic vaccination against chronic viral infections. Lancet Infect. Dis. 2, 353-367 (2002).
51. Hallez, S. et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53, 642-650 (2004).
52. Markowitz, M. et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunc- tive vaccination. J. Infect. Dis. 186, 634-643 (2002).
53. Buckner, C. et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320, 167-180 (2004).
54. Belshe, R.B. et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136, 168-175 (2000).
55. Sepulveda-Amor, J. et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 20, 2790-2795 (2002).
56. Jones, T. et al. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21, 3706-3712 (2003).
57. Tacket, C.O. Garden-variety vaccines: Antigens derived from transgenic plants. Expert Rev. Vaccines 3, 529-531 (2004).
58. Webster, D.E. et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol. 76, 7910-7912 (2002).
59. Stevceva, L. & Strober, W. Mucosal HIV vaccines: Where are we now? Curr. HIV Res. 2, 1-10 (2004).
60. Hammond, S.A., Walwender, D., Alving, C.R. & Glenn, G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19, 2701-2707 (2001).
61. Glenn, G.M., Kenney, R.T., Ellingsworth, L.R., Frech, S.A., Hammond, S.A. & Zoeteweij, J.P. Transcutaneous immunization and immunostimulant strategies: Capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2, 253-267 (2003).
62. Matyas, G.R., Friedlander, A.M., Glenn, G.M., Little, S., Yu, J. & Alving, C.R. Needle- free skin patch vaccination method for anthrax. Infect. Immun. 72, 1181-1183 (2004).
63. Chen, D. et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21, 2830-2836 (2003).
64. Mikszta, J.A., Alarcon, J.B., Brittingham, J.M., Sutter, D.E., Pettis, R.J. & Harvey, N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8, 415-419 (2002).
65. Finn, O.J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
66. Lewis, J.J. Therapeutic cancer vaccines: Using unique antigens. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14653-14656 (2004).
67. Hohlfeld, R. & Wekerle, H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14599-14606 (2004).
68. Petrovsky, N., Silva, D. & Schatz, D.A. Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr. Drugs 5, 575-582 (2003).
69. Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14677-14682 (2004).
70. Singh, M., Das, S.K., Suri, S., Singh, O. & Talwar, G.P. Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine. Am. J. Reprod. Immunol. 39, 395-398 (1998).
71. Mettens, P. & Monteyne, P. Life-style vaccines. Br. Med. Bull. 62, 175-186 (2002).
72. Gelinas, D.S., DaSilva, K., Fenili, D., George-Hyslop, P. & McLaurin, J. Immunotherapy for Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14657-14662 (2004).
73. Kantak, K.M., Collins, S.L., Lipman, E.G., Bond, J., Giovanoni, K. & Fox, B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology(Berl.) 148, 251-262 (2000).
74. Forsyth, K.D., et al. New pertussis vaccination strategies beyond infancy: Recommendations by the Global Pertussis Initiative. Clin. Infect. Dis. 39, 1802-1809 (2004).
75. Stanberry, L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl 3, 161A-169A (2004).
76. Arvin, A.M., Fast, P., Myers, M., Plotkin, S. & Rabinovich, R. Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39, 233-239 (2004).
77. Levin, M.J. et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J. Infect. Dis. 188, 1336-1344 (2003).
78. Baker, C.J., Paoletti, L.C., Rench, M.A., Guttormsen, H.K., Edwards, M.S. & Kasper, D.L. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J. Infect. Dis. 189, 1103-1112 (2004).
79. Munoz, F.M., Piedra, P.A. & Glezen, W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21, 3465-3467 (2003).
80. Fattom, A.I., Horwith, G., Fuller, S., Propst, M. & Naso, R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials. Vaccine 22, 880-887 (2004).
81. Hassani, M., Patel, M.C. & Pirofski, L.A. Vaccines for the prevention of diseases caused by potential bioweapons. Clin. Immunol. 111, 1-15 (2004).
82. McCurdy, L.H., Larkin, B.D., Martin, J.E. & Graham, B.S. Modified vaccinia Ankara: Potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38, 1749-1753 (2004).
83. WHO collaborative study group: The relationship between persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year enquiry. Bull WHO 60, 231-242 (1982).
84. Hoft, D.F. et al. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin. Infect. Dis. 28, 785-790 (1999).
85. Horwitz, M.A. & Harth, G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71, 1672-1679 (2003).
86. Morse, S.S. The viruses of the future? Emerging viruses and evolution. in The Evolutionary Biology of Viruses (ed Morse, S.S.) 325-335 (Raven Press, New York, 1994).
87. Matriano, J.A. et al. Macroflux microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm. Res. 19, 63-70 (2002).